GCG and atherosclerosis: In a similar study, Zelniker et al. (2019) indicated that GLP-1 RAs and SGLT-2 inhibitors reduce the risk of MACEs to an analogous degree in patients with established atherosclerotic cardiovascular disease (ASCVD).